U
SKBI

UBS’s SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) SKBI Stock Holding History

UBS’s Portfolio SKBI Stock Details SKBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-620
Closed -$4K – 11197
2014
Q1 		$4K Sell
620
-1,452
-70% -$7.35K ﹤0.01% 9767
2013
Q4 		$7K Buy
+2,072
New +$9.14K ﹤0.01% 9383
2013
Q3 		– Sell
-4,405
Closed -$6K – 11036
2013
Q2 		$6K Buy
+4,405
New +$6.24K ﹤0.01% 9181

Other funds holding SKBI

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Ativo Capital Management Chicago, Illinois $115M AUM 19.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

UBS's SKBI Position: Q2 2014 in Review

UBS sold out of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) in Q2 2014, closing a stake of 620 shares — an estimated $4K sold.

UBS first reported a position in SKBI in Q2 2013 and held it in 3 quarters. The position peaked at $7K in Q4 2013. 11 funds tracked by Wall St. Rank hold SKBI as of Q2 2014.

  • UBS reported no remaining SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position as of Q2 2014 after selling out during the quarter.
  • UBS sold 620 SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) shares in Q2 2014, an estimated $4K.
  • UBS first reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in Q2 2013 and held it in 3 quarters.
  • UBS's SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) position peaked at $7K in Q4 2013.
  • 11 funds tracked by Wall St. Rank held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.